Pathogenic mutant gene of hereditary central areolar retinopathy and detection reagent thereof

A retinopathy and hereditary technology, applied in the field of pathogenic mutations and detection reagents of hereditary central halo retinopathy, can solve the problems of cone cell degeneration, cone rod cell dystrophy, and no reports

CN105624167AInactive Publication Date: 2016-06-01JIANGSU PROVINCE HOSPITAL
0 Cites 4 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
Publication Date
2016-06-01
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a pathogenic mutant gene of hereditary central areolar retinopathy and a detection reagent thereof. The pathogenic mutant gene is a GUCA1A gene used for detecting hereditary central areolar retinopathy, and the mutant GUCA1A gene is heterozygously mutant GUCA1A p.Arg120Leu. Further disclosed is a kit for detecting hereditary central areolar retinopathy. The kit comprises a reagent for detecting nucleotide sites with physical positions of 42146547 and 42146548 of the GUCA1A gene, or a reagent for detecting 120th amino acid site of GCAP 1 protein (a) and a specification (b). Hereditary central areolar retinopathy can be diagnosed by detecting the mutant GUCA1A gene.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the field of biomedicine and relates to a pathogenic mutation of hereditary central halo retinopathy and a detection reagent thereof. Background technique

[0002] Central halo retinopathy (centralareolarchoidaldystrophy; CACD) is a group of progressive retinal degenerative diseases caused by genetic defects. The main pathological features of these diseases are the irreversible atrophy of retinal pigment epithelium (RPE) and choroidal blood vessels. CACD patients mainly harm the macular area of ​​the patient, causing a progressive decline in central vision, and severe cases can cause blindness. CACD is a clinically common and serious hereditary blinding disease, which can be divided into four stages according to its clinical features. Early CACD patients are difficult to make an accurate clinical diagnosis because their phenotypes are easily confused with other fundus disease patients. Therefore, it is particularly important ...

Examples

Embodiment 1

[0049] The GUCA1A gene mutation was detected in a five-generation family with central areolarchoidal dystrophy (CACD).

[0050] experimental method:

[0051] 1. Collection of clinical resources of the family and establishment of a genetic resource bank:

[0052] The clinical data and blood samples of each member of the family were collected, see the family diagram figure 1 . Clinical data mainly include personal medical history, family history, best corrected visual acuities (BCVAs), slit lamp examination, fundus photography, color vision examination, visual field examination (Humphrey perimetry), visual evoked potentials (visual-evokedpotentials; VEP), Electroretinography (ERG), fundus fluorescein angiography (FFA) and optical coherence tomography (OCT), etc. The blood genomic DNA of each family member was extracted with a blood genomic DNA extraction kit (Qiagen, Hilden, Germany).

[0053] 2. Discover the pathogenic mutations in this family with the help of high-throughp...

Embodiment 2

[0083] A functional study was carried out on the pathogenic mutation GUCA1Ap.Arg120Leu detected in Example 1.

[0084] experimental method:

[0085] 1. Conservative analysis:

[0086] The NCBI HomoloGene database (http: / / www.ncbi.nlm.nih.gov / homologene) was used to evaluate and predict the conservativeness of the screened mutations in multiple species.

[0087] 2. Research on protein crystal structure changes:

[0088] SWISSMODEL (http: / / swissmodel.expasy.org / ) prediction software was used to predict the structure of GUCA1A wild-type protein and the mutant protein carrying the p.Arg120Leu mutation, and evaluate the protein structure changes caused by the mutation.

[0089] 3. Zebrafish experiment:

[0090] Synthesize the full-length cDNA of wild type and mutant human GUCA1A gene respectively and clone it into pxT7 vector to construct pxT7 tagged GUCA1A WT and GUCA1A MU Plasmids, which are used to synthesize the corresponding GUCA1A mRNA, including GUCA1A WT and GUCA1A M...